Search

everythinglearnresearchcommunity

for

Search:↓

Combining stemoxydine with topical minoxidil for hair loss treatment. Users discuss application order and effectiveness, with some skepticism about stemoxydine's benefits.

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.

19-year-old with Lichen Planopilaris tried various treatments unsuccessfully. Now considering hair systems, seeking experiences and opinions.

Volunteers using finasteride and minoxidil are needed to test if intense calf raises increase hair shedding. The goal is to see if overexertion of leg muscles affects hair loss.

The conversation discusses treating male pattern baldness in a transgender woman using cyproterone acetate, finasteride, and biotin. The original poster shared their experience for others who might be in a similar situation.

The user was using 1mg finasteride daily and oral minoxidil 2.5mg daily for two years, then added RU58841 to their routine two months ago and is asking for opinions on any changes in hair growth. They provided progress pictures without dermarolling and maintained consistent lighting for comparison.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

User seeks treatment to increase minoxidil efficacy. Suggestions include microneedling, oral minoxidil, and Tretinoin, with mixed experiences and side effects.

A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.

Scientists discovered a potential baldness treatment from hairy moles, which can be injected like Botox. Users discussed the treatment's implications, including its safety and effectiveness.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

User asked dermatologist for finasteride, received latanoprost and diprogenta cream instead. Others suggest latanoprost is expensive and not better than minoxidil, recommend trying another doctor for finasteride.

A 26-year-old male experienced significant hair regrowth using a 4-in-1 topical treatment from Hims, which includes minoxidil, finasteride, ketoconazole, and biotin, over four months. The user reported increased body and beard hair, skin changes, and no negative sexual side effects, while others noted the rapid and impressive results as atypical.

The user is considering whether to get a second hair transplant or wait to see the results from switching to oral minoxidil and finasteride. They also use microneedling and ketoconazole shampoo.

A user shared a hair growth stack using minoxidil sulfate, valproic acid, bimatoprost, blue copper peptide, and other ingredients, emphasizing a gel-based formula for better skin tolerance. Another user suggested adding a 5-alpha-reductase inhibitor like finasteride or dutasteride for more effective long-term results.

The conversation discusses using 1% cetirizine, an antihistamine, as a potential treatment for androgenetic alopecia (hair loss). One user plans to try cetirizine instead of finasteride, while others are curious or skeptical about its effectiveness, discussing the role of inflammation in hair loss.

A user lost hair progress due to stress, poor nutrition, and lack of medication while in prison. They are now using a mix of natural oils and micro-needling, and plan to resume RU58841, dutasteride, and minoxidil.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

The post discusses a theory that hair regrowth after transplant is due to the angiogenesis process (new blood vessels forming), not because the transplanted hair is unaffected by DHT. The responses highlight the established belief in 'donor dominance' (the importance of the hair's origin in transplantation) and skepticism about the new theory.